drugset / Trial / NCT05459532
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
Phase 2/3
Completed
59 enrolled
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-centre, double-blind, phase 3 study to observe the effectiveness, safety, and tolerability of molnupiravir 800 mg administered 12-hourly for five days in adult patients with mild COVID-19 at the time of enrolment, who are at risk of progression to severe disease, compared to a placebo.
Timeline
- Start
- 2022-08-12
- Primary completion
- 2023-07-07
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Molnupiravir | Small molecule | 800 mg | Oral |